top of page


Company Overview

PURMX Therapeutics, Inc.


Headquarters : 1-2-3 Kasumi, Minami-ku, Hiroshima-city, Hiroshima 734-8553, JAPAN

Tokyo Office : No.7 Nihonbashi Lifescience Bldg, 1-9-10, Nihonbashi Horidome-cho, Chuo-ku, Tokyo 103-0012, JAPAN

Founded : January 2021


CEO/Representative Director and President

Hidetoshi Tahara

A world authority on aging research. While conducting research into aging and cancer, he succeeded in developing a unique technology for diagnosing aging based on telomere G-tail length, and founded a venture. As a professor at the Cell and Molecular Biology Laboratory at Hiroshima University, he led basic research with the motto "Aiming for world-class basic research that connects with patients," and identified microRNAs involved in cellular aging. In order to apply the results of his research to nucleic acid medicines as anti-cancer drugs, advocating the concept of an 'ageing switch' to turn on the ageing of cancer cells. He founded and led the management of his second venture, PURMX Therapeutics.

Board Director/Head of Clinical Development

Kazuhiro Takahashi

He has worked in the life sciences/pharmaceutical industry for approximately 40 years. He has a wide range of experience, from genetic engineering research such as gene cloning to clinical development. In his approximately 30-year career in clinical development, he has designed and managed over 10 domestic and oversea clinical protocols from Phase 1 to Phase 3. He has led the development of small molecules, antibody drugs, and DDS such as liposomes and micelles. He is mainly familiar with oncology area, but is also knowledgeable to the cardiovascular disease, CNS, and metabolic area.

Board Director/Head of Regulatory Affairs and Data Compliance

Masahiko Yasumoto

He has over 35 years of experience in pharmaceutical development, most of which has been spent in regulatory affairs and quality assurance. He has been involved in clinical development work across a wide range of formulations and therapeutic areas, from domestic FIH trials to global Phase 3 trials, and has discussed development plans with regulatory authorities in Canada and other Asian countries in addition to negotiating with the three-regional regulatory authorities of Japan, the United States, and Europe. He is responsible for a wide range of roles, from planning regulatory strategies to clinical development plans incorporating regulatory strategy. He also leads quality assurance work based on GXP, from non-clinical, clinical, and CMC.


PURMX Therapeutics was founded in 2021, but already has a system in place that allows it to take responsibility for drug development as a pharmaceutical venture.

The heads of research, clinical development, CMC, and regulatory affairs/quality assurance departments have an average of more than 30 years of experience in the pharmaceutical industry and are highly specialized. The heads of each department - non-clinical research that conducts pharmacology and safety evaluations, the clinical development department that draws up clinical development plans, the regulatory affairs/quality assurance department that is responsible for regulatory strategies and negotiations, and the CMC/investigational drug management department that is responsible for quality control of active pharmaceutical ingredients and formulations - share the knowledge they have gained through their experience in various drug developments with PURMX Therapeutics, supporting the company's functions as a full-functioning pharmaceutical venture.

In terms of business development, an experienced American outside director leads the business strategy and supports PURMX Therapeutics' overseas development and overseas business expansion.


bottom of page